A novel combination therapy with Cabozantinib and Honokiol effectively inhibits c-Met-Nrf2-induced renal tumor growth through increased oxidative stress is a research paper published in Redox Biology (2023). On theSindex it has a DataRank of 0.494. It has been cited 26 times.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.494
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →National Institutes of Health
Grant: R01 CA193675
National Institutes of Health
Grant: R01 CA222355
Dana-Farber/Harvard Cancer Center
Grant: 5P50CA101942-18
DF/HCC Kidney Cancer SPORE
NCI NIH HHS
Grant: P50 CA101942
National Institutes of Health
Grant: 5R01CA222355-02
Protective role of Honokiol in preventing c-Met-induced post-transplantation cancer
National Institutes of Health
Grant: 5R01CA193675-05
Novel Role(s) of Nrf2 in the Growth of Post-Transplantation Cancer
FWCI
2.48
Citation Percentile
0.9%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals